Intellia Therapeutics is advancing NTLA-2001, a CRISPR-based therapeutic targeting hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). The Phase 3 MAGNITUDE-2 trial aims to establish the efficacy and safety of a single infusion of NTLA-2001 compared to placebo. Given the increasing prevalence of ATTRv-PN and the limited treatment options currently available, successful outcomes could position NTLA-2001 as a leading therapy in a niche but growing market. The collaboration with Regeneron Pharmaceuticals may enhance development capabilities and market reach. However, the competitive landscape includes other emerging therapies targeting TTR, necessitating close monitoring of their clinical progress and market strategies.